Table 1.
Baseline clinical characteristics and laboratory parameters.
| Variable | Training Set (n = 86) | Validation Set (n = 44) | Immunotherapy Combined With Chemotherapy Set (n = 130) |
|---|---|---|---|
| Characteristics | |||
| Age, median, (25th, 75th) | 61.0 (53.0, 68.0) | 58.5 (51.2, 65.7) | 61 (53.0, 67.0) |
| Gender, n (%) | |||
| Male | 69 (80.23) | 33 (75.00) | 102 (78.46) |
| Female | 17 (19.77) | 11 (25.00) | 28 (21.54) |
| Smoking status, n (%) | |||
| Never | 28 (32.56) | 17 (38.64) | 45 (34.62) |
| Smoking | 58 (67.44) | 27 (61.36) | 85 (65.38) |
| Diabetes or hypertension, n (%) | |||
| No | 59 (68.60) | 32 (72.72) | 91 (70.00) |
| Yes | 27 (31.40) | 12 (27.28) | 39 (30.00) |
| BMI, n (%) | |||
| <18.5 | 9 (10.47) | 3 (6.81) | 12 (9.23) |
| 18.5-23.9 | 50 (58.14) | 26 (59.09) | 76 (58.46) |
| ≥24 | 27 (31.39) | 15 (34.10) | 42 (32.31) |
| Histology, n (%) | |||
| Squamous | 34 (39.53) | 21 (47.73) | 55 (42.31) |
| Adenocarcinoma | 50 (58.14) | 19 (43.18) | 69 (53.08) |
| Other NSCLC | 2 (2.32) | 4 (9.09) | 6 (4.61) |
| Clinical stage, n (%) | |||
| IIIA~IIIC | 12 (13.95) | 9 (20.45) | 21 (16.15) |
| IV | 74 (86.05) | 35 (79.55) | 109 (83.85) |
| N stage, n (%) | |||
| N0~N1 | 19 (22.09) | 6 (13.64) | 25 (19.23) |
| N2~N3 | 67 (77.91) | 38 (86.36) | 105 (80.77) |
| Number of metastatic organs, n (%) | |||
| ≤1 | 49 (56.98) | 27 (61.36) | 76 (58.46) |
| >1 | 37 (43.02) | 17 (38.64) | 54 (41.54) |
| Metastatic, n (%) | |||
| Brain | 19 (22.09) | 8 (18.18) | 27 (20.77) |
| Liver | 5 (5.81) | 7 (15.91) | 12 (9.23) |
| Bone | 30 (34.88) | 16 (36.36) | 46 (35.38) |
| Adrenal | 8 (9.30) | 4 (9.09) | 12 (9.23) |
| Pleural | 20 (23.25) | 15 (34.09) | 35 (26.92) |
| Contralateral lung | 33 (38.37) | 13 (29.55) | 46 (35.38) |
| Line of treatment, n (%) | |||
| 1 | 57 (66.28) | 33 (75.00) | 90 (69.23) |
| >1 | 29 (33.72) | 11 (25.00) | 40 (30.77) |
| Receipt of hormone treatment, n (%) | |||
| No | 26 (30.23) | 18 (40.91) | 44 (33.85) |
| Yes | 60 (69.77) | 26 (59.09) | 86 (66.15) |
| PD-L1 TPS%, n (%) | |||
| <1% | 20 (23.25) | 9 (20.46) | 29 (22.30) |
| 1%–49% | 21 (24.42) | 10 (22.73) | 31 (23.85) |
| ≥50% | 23 (26.74) | 8 (18.18) | 31 (23.85) |
| Unknown | 22 (25.58) | 17 (38.64) | 39 (30.00) |
| Laboratory parameters (25th, 75th) | |||
| LDH (IU/L) | 177 (150, 225) | 172 (139, 226) | 176 (146, 225) |
| RBC (×1012/L) | 4.32 (4.03, 4.76) | 4.23 (3.88, 4.66) | 4.29 (3.93, 4.71) |
| HB (g/L) | 130 (119, 142) | 126 (112, 136) | 128 (116, 141) |
| Platelet (×109/L) | 218 (166, 275) | 245 (187, 314) | 230 (171, 277) |
| WBC (×109/L) | 7.39 (5.45, 8.80) | 7.06 (5.05, 9.15) | 7.22 (5.38, 8.92) |
| ANC (×109/L) | 4.87 (3.60, 6.39) | 5.12 (3.27, 6.80) | 4.94 (3.50, 6.63) |
| AMC (×109/L) | 0.49 (0.37, 0.67) | 0.51 (0.34, 0.66) | 0.50 (0.36, 0.67) |
| ALC (×109/L) | 1.40 (0.91, 1.70) | 1.50 (1.01, 2.00) | 1.43 (0.96, 1.75) |
| AEC (×109/L) | 0.13 (0.05, 0.23) | 0.14 (0.08, 0.29) | 0.14 (0.07, 0.25) |
| dNLR | 2.19 (1.65, 3.30) | 2.40 (1.62, 3.56) | 2.20 (1.65, 3.31) |
| NLR | 3.54 (2.37, 5.83) | 3.76 (2.39, 5.96) | 3.54 (2.39, 5.83) |
| CEA (ng/ml) | 5.27 (1.81, 24.75) | 3.39 (1.87, 8.35) | 3.81 (1.81, 13.97) |
BMI, body mass index; NSCLC, non-non-small cell lung cancer; LDH, lactate dehydrogenase; RBC, red blood cell count; HB, hemoglobin; WBC, white blood cell count; ANC, absolute neutrophil count; AMC, absolute monocyte count; ALC, absolute lymphocyte count; AEC, absolute eosinophil count; dNLR, derived neutrophil-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; CEA, carcinoembryonic antigen.